NeurologyLive® Friday 5 — October 31, 2025

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: 2025 CNS Annual Meeting: Top Expert Interviews and Key Takeaways

Experts shared their clinical perspectives on trending topics in the treatment and management of multiple sclerosis at the 54th Child Neurology Society (CNS) Annual Meeting, held October 8-11, 2025.

2: Key Diagnostic Pearls for NMOSD Recognition and Testing: Elena Grebenciucova, MD

The assistant professor of neurology at Northwestern University shared important clinical insights for early-career clinicians entering neuroimmunology, emphasizing best practices in recognizing, testing, and confirming NMOSD. [WATCH TIME: 3 minutes]

3: Rethinking Inclusion Criteria to Increase Generalizability, Patient Participation in Parkinson Disease Trials: Camille Carroll, MD

At MDS 2025, professor of clinical neuroscience at Newcastle University discussed selecting appropriate and representative patient populations across different phases of clinical trials for Parkinson disease. [WATCH TIME: 5 minutes]

4: NeuroVoices: Mitch Elkind, MD, MS, FAHA, on Enhancing Brain Health Amid World Stroke Day

The chief science officer at the American Heart Association discusses its priorities for stroke prevention, cross-specialty collaboration, and equitable care as clinicians mark World Stroke Day 2025.

5: Overviewing Long-Term Efficacy of Zorevunersen From IEC 2025

Epilepsy expert Joseph Sullivan, MD, reviews 36-month results from the zorevunersen program, highlighting durable seizure reduction and sustained efficacy following dose optimization. [WATCH TIME: 4 minutes]